当前位置： SCI文献检索 > CANCER CHEMOTHERAPY AND PHARMACOLOGY期刊下所有文献 > Effects of verapamil on the pharmacokinetics and metabolism of epirubicin.

Effects of verapamil on the pharmacokinetics and metabolism of epirubicin.

Abstract：

:Experimental data suggest that multidrug resistance in cancer may be overcome by using an increased dose of anticancer agent(s) in combination with a resistance-modifying agent (RMA). We studied the pharmacokinetics and metabolism of both epirubicin (EPI) and verapamil (VPL) to explore the possible pharmacokinetic interactions between these two drugs. Ten patients with advanced breast cancer were given EPI (40 mg/m2 in a daily i.v. bolus for 3 consecutive days), and five of them also received VPL (4 x 120 mg/daily p.o. for 4 consecutive days). The data indicated a significant interaction between these two drugs that affected their metabolism. The areas under the concentration-time curves (AUC) obtained for epirubicin glucuronide, epirubicinol glucuronide, and both of the 7-deoxy-aglycones were higher in the EPI + VPL group as compared with the EPI group. The AUC, terminal half-life, mean residence time, volume of distribution at steady state, and plasma clearance of EPI alone as compared with EPI + VPL did not differ significantly. These results suggest either an induction of enzymes necessary for drug metabolism or an increase in the liver blood flow, resulting in an enhanced generation of metabolites with time or in an inhibition of excretion processes. Comparisons of the AUC values obtained for EPI and its metabolites after the first, second, and third injections of EPI revealed a cumulative effect for the metabolites that was more pronounced in the EPI + VPL group, being significant (P < 0.05) for epirubicin glucuronide in both treatment groups and for epirubicinol glucuronide in the EPI + VPL group. Maximal concentrations of VPL and nor-VPL reached 705 +/- 473 and 308 +/- 122 ng/ml, respectively, with the steady-state concentrations being 265 +/- 42 ng/ml for VPL and 180 +/- 12 ng/ml for nor-VPL.

journal_name

Cancer Chemother Pharmacol

journal_title

Cancer chemotherapy and pharmacology

authors

Mross K,Hamm K,Hossfeld DK

doi

10.1007/BF00686150

subject

Has Abstract

pub_date

1993-01-01 00:00:00

pages

369-75

issue

5

eissn

0344-5704

issn

1432-0843

journal_volume

31

pub_type

杂志文章

相关文献

CANCER CHEMOTHERAPY AND PHARMACOLOGY文献大全
  • Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study.

    abstract：PURPOSE:Bevacizumab or temsirolimus regimens have clinical activity in the first-line treatment of advanced renal cell carcinoma (RCC). This phase I/II trial was conducted to determine the safety of combining both agents and its efficacy in RCC patients who progressed on at least one prior anti-VEGF receptor tyrosine k...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-014-2668-5

    authors： Merchan JR,Qin R,Pitot H,Picus J,Liu G,Fitch T,Maples WJ,Flynn PJ,Fruth BF,Erlichman C

    更新日期：2015-03-01 00:00:00

  • IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells.

    abstract：BACKGROUND:Inhibitors of heat shock protein (Hsp) 90 induce apoptosis in multiple myeloma (MM) cells, but the molecular mechanisms underlying this cytotoxic outcome are not clear. Here, we investigate the effect of IPI-504, a novel and highly soluble inhibitor of the Hsp90 ATPase activity, on the unfolded protein respo...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-007-0546-0

    authors： Patterson J,Palombella VJ,Fritz C,Normant E

    更新日期：2008-05-01 00:00:00

  • A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid tumors.

    abstract：PURPOSE:PF-00337210 is an oral, highly selective vascular endothelial growth factor receptor (VEGFR) inhibitor. We evaluated a composite of biomarkers in real time to identify the recommended phase 2 dose (RP2D) and preliminary anticancer activity of PF-00337210. PATIENTS AND METHODS:Patients (Pts) with advanced cance...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-016-2958-1

    authors： Bruce JY,LoRusso PM,Goncalves PH,Heath EI,Sadowski E,Shalinsky DR,Zhang Y,Traynor AM,Breazna A,Ricart AD,Tortorici M,Liu G

    更新日期：2016-03-01 00:00:00

  • Interactions of carboxypeptidase G2 with 6S-leucovorin and 6R-leucovorin in vitro: implications for the application in case of methotrexate intoxications.

    abstract：:Carboxypeptidase G2 (CPG2) is used when unexpected toxicity or renal failure occurs during high-dose methotrexate therapy. Leucovorin is also administered to antagonise the effects of methotrexate on purine anabolism. To investigate the effects of CPG2 on leucovorin rescue, we incubated the enzyme with both stereoisom...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-004-0910-2

    authors： Hempel G,Lingg R,Boos J

    更新日期：2005-04-01 00:00:00

  • Sonodynamic therapy with photofrin II on AH130 solid tumor. Pharmacokinetics, tissue distribution and sonodynamic antitumoral efficacy of photofrin II.

    abstract：BACKGROUND:The pharmacokinetics and tissue distribution of photofrin II (PF) and its efficacy in sonodynamic therapy were studied in rats bearing AH130 solid tumors. MATERIALS AND METHODS:In order to find the optimum timing of the ultrasound exposure after administration of PF, the PF concentrations in plasma, skin, m...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-002-0523-6

    authors： Yumita N,Umemura S

    更新日期：2003-02-01 00:00:00

  • Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours.

    abstract：PURPOSE:To evaluate the antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a vascular disrupting agent currently under phase II clinical trials in combination with cancer chemotherapy, in rats bearing chemically induced primary mammary tumours. METHODS:Tumours were induced in female Wistar rats by in...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-006-0321-7

    authors： Liu JJ,Ching LM,Goldthorpe M,Sutherland R,Baguley BC,Kirker JA,McKeage MJ

    更新日期：2007-04-01 00:00:00

  • Further characterization of the sixth transmembrane domain of Pgp1 by site-directed mutagenesis.

    abstract：PURPOSE:Several studies have identified amino acid residues located on the hydrophobic side of the helix that forms transmembrane domain 6 (TM6) of the ABC transporter P-glycoprotein (Pgp) as being important for function. The purpose of this study was to determine if alterations to residues on the hydrophilic side coul...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s002800100354

    authors： Song J,Melera PW

    更新日期：2001-11-01 00:00:00

  • In vitro effect of r-verapamil on acute myelogenous leukemia blast cells: studies of cytokine secretion and cytokine-dependent blast proliferation.

    abstract：:The in vitro effect of the dextroisomer r-verapamil on blast cells derived from patients with acute myelogenous leukemia (AML) was studied. R-verapamil caused a dose-dependent inhibition of AML blast proliferation in the presence of stem-cell factor, leukemia inhibitory factor, interleukin 4, interleukin 6, and interl...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00685631

    authors： Bruserud O,Nesthus I,Pawelec G

    更新日期：1995-01-01 00:00:00

  • Phase I study of high-dose cisplatin, ifosfamide, and etoposide.

    abstract：:To test the feasibility of a regimen of high-dose cisplatin, ifosfamide, and etoposide (VP-16; VIPP regimen), we registered 15 patients with advanced non-small-cell lung cancer in a phase I trial of the Northern California Oncology Group. One cycle of treatment consisted of high-dose cisplatin given at 100 mg/m2 i.v. ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章

    doi：10.1007/BF00686041

    authors： Perez EA,Sowray PC,Gardner SL,Gandara DR

    更新日期：1994-01-01 00:00:00

  • Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro.

    abstract：:The cytotoxicity of cisplatin alone and in combination with topotecan (TPT) or SN-38, two novel topoisomerase I (topo I) inhibitors, was determined in a panel of eight well-characterized human solid-tumor cell lines. Interactions between cisplatin and these topo I inhibitors were investigated using three different adm...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s002800050744

    authors： Ma J,Maliepaard M,Nooter K,Boersma AW,Verweij J,Stoter G,Schellens JH

    更新日期：1998-01-01 00:00:00

  • BCNU-induced quantitative and qualitative changes in hepatic cytochrome P-450 can be correlated with cholestasis.

    abstract：:Male Sprague-Dawley rats were given single i.p. injections of 1,3-bis(2-chloroethyl)-1-Nitrosourea (BCNU) to investigate changes in hepatic microsomal cytochrome P-450 content and metabolic activity. On day 14 after treatment (20 mg/kg), cytochrome P-450 content had decreased by approximately 25% and ethylmorphine N-d...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00684877

    authors： Stolzenbach JC,Larson RE

    更新日期：1990-01-01 00:00:00

  • Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors.

    abstract：PURPOSE:Erlotinib (Tarceva®), a potent small molecule inhibitor of the epidermal growth factor receptor tyrosine kinase, has been evaluated to treat infants and children with primary brain tumors. The pharmacokinetics of erlotinib and its primary metabolite OSI-420 were characterized and exposure-safety associations we...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1007/s00280-019-03921-3

    authors： Reddick SJ,Campagne O,Huang J,Onar-Thomas A,Broniscer A,Gajjar A,Stewart CF

    更新日期：2019-10-01 00:00:00

  • Development of anti-angiogenic tyrosine kinases inhibitors: molecular structures and binding modes.

    abstract：PURPOSE:Since the hypothesis that solid tumors cause angiogenesis by secreting pro-angiogenic factors was introduced, research on angiogenesis has proceeded continuously. Development of inhibitors targeting the angiogenic tyrosine kinases, to block downstream signal transduction pathways, has become an important approa...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,评审

    doi：10.1007/s00280-016-2961-6

    authors： Zhang J,Zhang L,Wang Y,Zhao G

    更新日期：2016-05-01 00:00:00

  • Clinical effects of combination therapy with mitoxantrone, vincristine, and prednisolone in breast cancer.

    abstract：PURPOSE:We assessed the clinical efficacy and safety of mitoxantrone hydrochloride which has been used as an anticancer drug in our hospital to treat breast cancer patients since 1993. METHODS:A group of 23 patients with breast cancer were given one course of the following regimen every 3 weeks: mitoxantrone hydrochlo...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-003-0586-z

    authors： Katsumata K,Tomioka H,Kusama M,Aoki T,Koyanagi Y

    更新日期：2003-07-01 00:00:00

  • The role of methoxymorpholino anthracycline and cyanomorpholino anthracycline in a sensitive small-cell lung-cancer cell line and its multidrug-resistant but P-glycoprotein-negative and cisplatin-resistant counterparts.

    abstract：:The cytotoxic action of two morpholino anthracyclines, methoxymorpholino anthracycline (MRA-MT, FCE 23,762) and cyanomorpholino anthracycline (MRA-CN), was compared with the cytotoxicity of doxorubicin (DOX), the topoisomerase II inhibitor etoposide (VP-16), the topoisomerase I inhibitor camptothecin, methotrexate, an...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00689457

    authors： van der Graaf WT,Mulder NH,Meijer C,de Vries EG

    更新日期：1995-01-01 00:00:00

  • Evaluation of p-F-Phe-m-bis-(2-chloroethyl)amino-L-Phe-Met-ethoxy HCl against transplantable and spontaneous murine neoplasia.

    abstract：:The therapeutic efficacy of PTT.119, p-F-Phe-m-bis-(2-chloroethyl)amino-L-Phe-Met-ethoxy HCl, was evaluated using the transplantable L1210 leukemia and Ridgway osteogenic sarcoma tumor lines and the spontaneous C3H/StRos mammary tumor and AKR leukemia tumor models. Given in a single i.p. dose at 5-10 mg/kg on day 2 or...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF02897202

    authors： Yagi MJ,Bekesi JG

    更新日期：1990-01-01 00:00:00

  • Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine.

    abstract：PURPOSE:Curcumin, a major constituent of the spice turmeric, suppresses expression of the enzyme cyclooxygenase 2 (Cox-2) and has cancer chemopreventive properties in rodents. It possesses poor systemic availability. We explored whether formulation with phosphatidylcholine increases the oral bioavailability or affects ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-006-0355-x

    authors： Marczylo TH,Verschoyle RD,Cooke DN,Morazzoni P,Steward WP,Gescher AJ

    更新日期：2007-07-01 00:00:00

  • Pharmacokinetics of abiraterone in healthy Japanese men: dose-proportionality and effect of food timing.

    abstract：PURPOSE:Abiraterone acetate (AA) was recently approved for castration-resistant prostate cancer in Japan. Two phase 1 studies were conducted to assess the pharmacokinetics of abiraterone after single-dose administration in Japanese healthy men and to evaluate the effects of food timing on abiraterone pharmacokinetics a...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1007/s00280-014-2616-4

    authors： Inoue K,Shishido A,Vaccaro N,Jiao J,Stieltjes H,Bernard A,Yu M,Chien C

    更新日期：2015-01-01 00:00:00

  • Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers.

    abstract：PURPOSE:Our study was designed to evaluate the efficacy and safety of everolimus in patients with pre-treated metastatic gastric and esophagus cancers in a US-based population focusing on biomarker correlation. METHODS:Patients with advanced upper GI adenocarcinomas who progressed after 1-2 prior regimens received eve...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s00280-015-2744-5

    authors： Wainberg ZA,Soares HP,Patel R,DiCarlo B,Park DJ,Liem A,Wang HJ,Yonemoto L,Martinez D,Laux I,Brennan M,Hecht JR

    更新日期：2015-07-01 00:00:00

  • In vivo measurement of myocardial oxidative metabolism and blood flow does not show changes in cancer patients undergoing doxorubicin therapy.

    abstract：PURPOSE:The aim was to investigate in patients receiving doxorubicin whether any alteration in myocardial oxidative metabolism or blood flow as assessed by positron emission tomography (PET) could be observed either after the first dose of the drug, or during its chronic administration. METHODS:Six female non-heart-fa...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s002800051005

    authors： Nony P,Guastalla JP,Rebattu P,Landais P,Lievre M,Bontemps L,Itti R,Beaune J,Andre-Fouet X,Janier M

    更新日期：2000-01-01 00:00:00

  • Successful treatment of a patient with acute nonlymphoblastic leukemia (ANLL) and anthracycline cardiomyopathy with 4' (9-acridinylamino) methanesulfon-m-anisidide (AMSA).

    abstract：:A patient with acute nonlymphoblastic leukemia in relapse and anthracycline cardiomyopathy was treated with AMSA in combination with cytosine arabinoside and thioguanine (AAT). Induction of remission was accomplished after one course of therapy without development of congestive heart failure. Radionuclide studies done...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00257232

    authors： Fanucchi MP,Arlin ZA

    更新日期：1982-12-01 00:00:00

  • Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients.

    abstract：PURPOSE:The relationships between pharmacokinetic parameters of unchanged cisplatin (CDDP) and several markers for nephrotoxicity after CDDP infusion (80 mg/m2) over 2 and 4 h were quantitated in patients with various cancers (lung, stomach and colon cancers and mediastinal tumor). METHODS:Plasma and urinary levels of...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s002800050548

    authors： Nagai N,Kinoshita M,Ogata H,Tsujino D,Wada Y,Someya K,Ohno T,Masuhara K,Tanaka Y,Kato K,Nagai H,Yokoyama A,Kurita Y

    更新日期：1996-01-01 00:00:00

  • A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study.

    abstract：PURPOSE:The addition of cetuximab to triplet chemotherapy can increase treatment efficacy for patients with metastatic colorectal cancer (mCRC). We explored the dose-limiting toxicity and feasibility of a triweekly capecitabine, oxaliplatin, irinotecan, plus cetuximab (XELOXIRI plus cetuximab) regimen in patients with ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-017-3458-7

    authors： Sato Y,Hirakawa M,Ohnuma H,Takahashi M,Okamoto T,Okamoto K,Miyamoto H,Muguruma N,Furuhata T,Takemasa I,Kato J,Takayama T

    更新日期：2017-12-01 00:00:00

  • A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose.

    abstract：PURPOSE:To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), safety, pharmacokinetics, and pharmacodynamics of SB-743921 when administered as a 1-h infusion every 21 days to patients with advanced solid tumors or relapsed/refractory lymphoma. METHODS:Patients who failed prior standard therapy o...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-010-1346-5

    authors： Holen KD,Belani CP,Wilding G,Ramalingam S,Volkman JL,Ramanathan RK,Vasist LS,Bowen CJ,Hodge JP,Dar MM,Ho PT

    更新日期：2011-02-01 00:00:00

  • Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines.

    abstract：PURPOSE:The aim of this study is to examine the factors affecting sensitivity to cisplatin, carboplatin, and oxaliplatin in human colorectal tumor cell lines. METHODS:Caco-2, DLD-1, HCT-15, HCT116, LS180, SW620, and WiDr cells were used. Their growth inhibition by platinum derivatives was evaluated with a WST-1 assay ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-007-0640-3

    authors： Kitada N,Takara K,Minegaki T,Itoh C,Tsujimoto M,Sakaeda T,Yokoyama T

    更新日期：2008-09-01 00:00:00

  • Cellular pharmacology of D-3-azido-3-deoxy-myo-inositol, an inhibitor of phosphatidylinositol signaling having antiproliferative activity.

    abstract：:D-3-Azido-3-deoxy-myo-inositol (3AMI) is an inhibitor of the growth of v-sis-transformed NIH 3T3 cells but not of wild-type NIH 3T3 cells, whose effects may be mediated through the phosphatidylinositol-3'-kinase pathway. We studied some properties of the cellular pharmacology of 3AMI using high-specific-activity [3H]-...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00686287

    authors： Brunn G,Fauq AH,Chow S,Kozikowski AP,Gallegos A,Powis G

    更新日期：1994-01-01 00:00:00

  • Comparative studies of DNA cross-linking reactions following methylene dimethanesulphonate and its hydrolytic product, formaldehyde.

    abstract：:The technique of alkaline elution was employed to study the interactions of methylene dimethane sulphonate (MDMS) and formaldehyde (HCHO) with DNA from Yoshida lymphosarcoma cells treated with these agents. MDMS and HCHO produced a proteinase sensitive filter retention which indicated the presence of DNA-protein cross...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00296247

    authors： O'Connor PM,Fox BW

    更新日期：1987-01-01 00:00:00

  • High-dose VP16 cisplatinum in soft tissue sarcoma of children.

    abstract：:Nine children with soft tissue sarcomas, five of them rhabdomyosarcomas with initial metastatic disease, (one patient, partial response, one patient), refractory primary, (two patients, relapse, five patients) were treated with a combination of high-dose VP16 (100 mg/m2 daily for 5 days) and cisplatin (40 mg/m2 daily ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00685912

    authors： Grabois M,Frappaz D,Bouffet E,Carrie C,Bouhour D,Philip T,Brunat-Mentigny M

    更新日期：1994-01-01 00:00:00

  • Receptor occupancy theory-based analysis of antiemetic effects and standard doses of 5-HT3 receptor antagonists in cancer patients.

    abstract：PURPOSE:The aim of this study was to determine the usefulness of receptor occupancy theory-based analysis using pharmacokinetic and pharmacodynamic parameters for predicting the average receptor occupancy (PhiB) in humans of each of five 5-HT3 antagonists administered at standard doses. METHODS:The relationship betwee...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-004-0798-x

    authors： Yamada Y,Sugiura M,Higo K,Ozeki T,Takayanagi R,Okuyama K,Yamamoto K,Satoh H,Sawada Y,Iga T

    更新日期：2004-08-01 00:00:00

  • Efficacy and safety of irinotecan monotherapy as third-line treatment for advanced gastric cancer.

    abstract：PURPOSE:Although irinotecan monotherapy is often used in third-line treatment after the failure of taxanes in Japanese clinical practice, its survival benefit is still unclear. The aim of this study is to investigate the efficacy and safety of irinotecan monotherapy as third-line treatment. METHODS:Clinical data from ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-016-3138-z

    authors： Kawakami T,Machida N,Yasui H,Kawahira M,Kawai S,Kito Y,Yoshida Y,Hamauchi S,Tsushima T,Todaka A,Yokota T,Yamazaki K,Fukutomi A,Onozawa Y

    更新日期：2016-10-01 00:00:00